REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Jul 31, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-07-27

Reporting Person: Terifay Robert J (SVP Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-27	Common Stock	M	14000.0	$16.8	Acquired	23372.0	Direct
2012-07-27	Common Stock	F	1711.0	$137.39	Disposed	21661.0	Direct
2012-07-27	Common Stock	F	5661.0	$137.39	Disposed	16000.0	Direct
2012-07-27	Common Stock	M	24375.0	$16.8	Acquired	40375.0	Direct
2012-07-27	Common Stock	F	2980.0	$137.39	Disposed	37395.0	Direct
2012-07-27	Common Stock	F	9856.0	$137.39	Disposed	27539.0	Direct
2012-07-27	Common Stock	M	12500.0	$21.92	Acquired	40039.0	Direct
2012-07-27	Common Stock	F	1994.0	$137.39	Disposed	38045.0	Direct
2012-07-27	Common Stock	F	4839.0	$137.39	Disposed	33206.0	Direct
2012-07-30	Common Stock	S	67.0	$134.99	Disposed	33139.0	Direct
2012-07-30	Common Stock	S	14833.0	$135.49	Disposed	18306.0	Direct
2012-07-30	Common Stock	S	6600.0	$136.26	Disposed	11706.0	Direct
2012-07-30	Common Stock	S	2334.0	$137.58	Disposed	9372.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-07-27	Non-Qualified Stock Option (right to buy)	$16.8	M	14000.0	Disposed	2018-12-17	Common Stock (14000.0)	Direct
2012-07-27	Non-Qualified Stock Option (right to buy)	$16.8	M	24375.0	Disposed	2018-12-17	Common Stock (24375.0)	Direct
2012-07-27	Non-Qualified Stock Option (right to buy)	$21.92	M	12500.0	Disposed	2017-12-17	Common Stock (12500.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1531.0	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 14,833 shares of Company stock on July 30, 2012 at prices ranging from $135.02 to $135.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 30, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 6,600 shares of Company stock on July 30, 2012 at prices ranging from $136.00 to $136.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 30, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 2,334 shares of Company stock on July 30, 2012 at prices ranging from $137.30 to $137.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 30, 2012 at each separate price.

F5: On December 17, 2008, the reporting person was granted an option to purchase 48,750 shares of Common Stock. The option was eligible to vest, partially or in full, on December 31, 2011, based on the extent to which the company satisfied certain performance criteria. The performance criteria were met and the option vested as to all shares.

F6: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

F7: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F8: The stock option award vests in four equal annual installments, commencing one year after the date of grant.